ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

Oklahoma ,United States ,University Of Oklahoma ,Waltham ,Massachusetts ,Paris ,France General ,France ,Anabel Chan ,Kathleen Moore ,Courtney Okonek ,Robert Stanislaro ,Anna Berkenblit ,Ursulaa Matulonis ,Kathleenn Moore ,Phasei Program ,Exchange Commission On ,Company Quarterly Reports On Form ,Nasdaq ,Exchange Commission ,Company Annual Report On Form ,University Of Oklahoma College Medicine ,Forwardi Co ,European Society For Medical Oncology ,Immunogen Inc ,European Society ,Medical Oncology ,Senior Vice President ,Chief Medical Officer ,Priority Review ,Gynecologic Oncology ,Oklahoma College ,Annual Report ,Quarterly Reports ,Business Wire ,Health ,Covid 19 ,Europe ,Business ,Cancer ,Chemotherapy ,Clinical Trials ,Ovarian Cancer ,